APA (7th ed.) Citation

White, H. D., Bhatt, D. L., Gibson, C. M., Hamm, C. W., Mahaffey, K. W., Price, M. J., . . . Harrington, R. A. (2015). Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: Insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC. Cardiovascular interventions, 8(3), 424. https://doi.org/10.1016/j.jcin.2014.09.025

Chicago Style (17th ed.) Citation

White, Harvey D., et al. "Outcomes with Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])." JACC. Cardiovascular Interventions 8, no. 3 (2015): 424. https://doi.org/10.1016/j.jcin.2014.09.025.

MLA (9th ed.) Citation

White, Harvey D., et al. "Outcomes with Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])." JACC. Cardiovascular Interventions, vol. 8, no. 3, 2015, p. 424, https://doi.org/10.1016/j.jcin.2014.09.025.